We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Culturally Tailored Meal Program Reduces Hospitalizations in Navajo Patients With Heart Failure: The MUTTON-HF Trial

MedXY Editorial Team•Jul 29, 2026•Cardiology
heart failureThực Phẩm là Thuốcquality of lifeclinical trialdietary interventionhospitalizationsIndigenous health
  • An 8-week culturally tailored meal program reduced the risk of all-cause hospitalization or ED visit by 28% in Navajo patients with heart failure.

  • The benefit was driven mainly by fewer hospitalizations (12.3% vs 26.0%), including heart failure-specific hospitalizations (3.8% vs 13.0%).

  • Patients receiving the intervention reported improved quality of life, reduced food insecurity, and lower blood pressure and weight.

  • Adverse events were uncommon, though the study was open-label.

  • Population: 206 adults with heart failure, mean age 66, 42% female, from two Indian Health Service sites in Navajo Nation.

  • Intervention: 8 weeks of culturally and medically tailored meals (traditional Navajo foods) vs usual dietary advice.

  • Primary endpoint: Proportion with all-cause hospitalization or ED visit within 90 days.

  • Primary result: 40.6% vs 57.0%; RR 0.72 (95% CI 0.54–0.96; P=0.02).

  • Safety: Adverse events uncommon (details not fully reported in abstract).

A Culturally Rooted Approach to Heart Failure Care

Nutrition insecurity is a well-recognized driver of poor cardiovascular health in Indigenous communities. Despite high rates of heart failure, few interventions have been designed to address both the medical and cultural needs of these populations. The MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure) trial evaluated whether a program that provides medically tailored meals based on traditional Navajo foods could improve clinical outcomes in patients with heart failure living in the Navajo Nation.

Study Design and Participants

This pragmatic, open-label randomized clinical trial was conducted from May to November 2025 at two Indian Health Service sites in rural Navajo Nation. Eligible adults had heart failure with at least one hospitalization or emergency department visit in the prior 12 months. A total of 206 patients (mean age 65.8 years, 42% female, 99% American Indian) were randomized 1:1 to receive either 8 weeks of a culturally and medically tailored meal program (which incorporated traditional Navajo foods such as mutton, blue corn, and vegetables) or usual dietary advice. All patients were followed for 12 weeks for outcomes and adverse events.

Primary Endpoint Met: Fewer Hospitalizations and ED Visits

The primary endpoint was the proportion of patients with an all-cause hospitalization or emergency department visit within 90 days. The intervention group had a significantly lower rate: 40.6% (43 patients) compared with 57.0% (57 patients) in the usual-advice group. The relative risk was 0.72 (95% CI 0.54–0.96; P=0.02), corresponding to a 28% reduction.

The benefit was driven primarily by a lower rate of hospitalizations: 12.3% (13 patients) in the arm receiving meals versus 26.0% (26 patients) in the control group. Heart failure-specific hospitalizations were also reduced: 3.8% (4 patients) vs 13.0% (13 patients). The number of emergency department visits showed a smaller difference, but the composite primary endpoint achieved statistical significance.

Secondary Outcomes: Quality of Life and Food Security Improved

Several secondary endpoints favored the intervention. Scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ), a measure of heart failure-related quality of life, improved significantly more in the meal-program group. Food security measures also increased, while measures of financial strain decreased. In addition, systolic and diastolic blood pressure and body weight declined modestly but significantly in the intervention arm. The authors noted that the changes in blood pressure and weight were consistent with the overall cardiovascular benefits seen in the primary endpoint.

Safety Was Acceptable

Adverse events were reported as uncommon, though the abstract does not provide a detailed breakdown. No unexpected safety signals emerged. Because the trial was open-label, patient-reporting bias cannot be excluded.

Limitations and Interpretation

The pragmatic design and open-label nature are important limitations, as patients and clinicians were aware of treatment assignment. The study enrolled exclusively Navajo patients, so generalizability to other Indigenous or non-Indigenous populations is not established. The intervention lasted only 8 weeks, with outcome assessment at 90 days; longer-term durability of the effect is unknown. Nonetheless, the trial provides evidence that a culturally tailored food-as-medicine intervention can reduce hospitalizations and improve quality of life in a high-risk population. The results underscore the potential of community-based interventions that leverage protective assets of Native communities.

Funding and Trial Registration

The study was registered at ClinicalTrials.gov (NCT06549699). Funding sources were not listed in the abstract.

References

  1. Eberly LA, George C, Sandman S, et al. An Indigenous Food Is Medicine Intervention: The MUTTON-HF Randomized Clinical Trial. JAMA Internal Medicine. 2026; published online July 27. PMID: 42507456.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Unraveling the Clinical Complexity of Extremely High NT-proBNP in Hospitalized Adults: Beyond Heart FailureExtremely high NT-proBNP levels in hospitalized patients often indicate infection rather than heart failure, with a high mortality risk; interpretation requires comprehensive clinical context.Sep 27, 2026Laparoscopic Radiofrequency Ablation versus Myomectomy: Comparative Effects on Uterine Leiomyoma Symptoms and Quality of LifeA multicenter prospective study comparing laparoscopic radiofrequency ablation and myomectomy in symptomatic uterine leiomyomas reveals both improve symptoms and quality of life, with myomectomy showing modest but clinically non-significantSep 25, 2026Cardiac Resynchronization Therapy With or Without Atrioventricular Node Ablation in Atrial Fibrillation: The CAAN-AF TrialThis trial evaluated whether atrioventricular node ablation improves outcomes of cardiac resynchronization therapy in heart failure patients with permanent atrial fibrillation, finding no significant benefit over medical rate control.Sep 25, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Long-Term Quality of Life Outcomes in Older Patients Undergoing Heart Transplantation or Mechanical Circulatory Support: Insights from the SUSTAIN-IT Study
The SUSTAIN-IT study reveals variable improvements in health-related quality of life over two years following heart transplantation or long-term mechanical circulatory support in older heart failure patients, highlighting important consider
Sep 23, 2026
Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior StudiesDapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.Sep 22, 2026
Bridging Evidence-Based and Personalized Medicine in Heart Failure and Cardiomyopathies: Balancing Standardization with IndividualizationThis article explores the integration of evidence-based medicine and personalized approaches in managing heart failure and inherited cardiomyopathies, proposing a framework to optimize patient care by harmonizing standardized guidelines witSep 17, 2026